Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

625 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
Piccart MJ, Bruning P, Wildiers J, Awada A, Schornagel JH, Thomas J, Tomiak E, Bartholomeus S, Witteveen PO, Paridaens R. Piccart MJ, et al. Ann Oncol. 1995 Sep;6(7):673-7. doi: 10.1093/oxfordjournals.annonc.a059283. Ann Oncol. 1995. PMID: 8664188 Free article. Clinical Trial.
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Piccart MJ, et al. J Clin Oncol. 1997 Sep;15(9):3149-55. doi: 10.1200/JCO.1997.15.9.3149. J Clin Oncol. 1997. PMID: 9294478 Clinical Trial.
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.
Hamilton A, Roy JA, Beex L, Piccart M, Mauriac L, Coleman R, Paridaens R, Boes GH, van Vreckem A, Palmer P, Klijn J. Hamilton A, et al. Among authors: piccart m. Breast Cancer Res Treat. 2000 Mar;60(2):181-8. doi: 10.1023/a:1006398518037. Breast Cancer Res Treat. 2000. PMID: 10845281 Clinical Trial.
Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer.
Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R. Kramer JA, et al. Among authors: piccart m. Eur J Cancer. 2000 Aug;36(12):1498-506. doi: 10.1016/s0959-8049(00)00144-1. Eur J Cancer. 2000. PMID: 10930797 Free article. Clinical Trial.
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
Hamilton A, Larsimont D, Paridaens R, Drijkoningen M, van de Vijver M, Bruning P, Hanby A, Houston S, Treilleux I, Guastalla JP, Van Vreckem A, Sylvester R, Piccart M. Hamilton A, et al. Among authors: piccart m. Clin Breast Cancer. 2000 Oct;1(3):233-40; discussion 241-2. doi: 10.3816/CBC.2000.n.020. Clin Breast Cancer. 2000. PMID: 11899648 Clinical Trial.
625 results